| 词条 | Iniparib |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 461935906 | IUPAC_name = 4-Iodo-3-nitrobenzamide | image = Iniparib.svg | width = 175 | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Development terminated | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 160003-66-7 | ATC_prefix = None | ATC_suffix = | PubChem = 9796068 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 7971834 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 2ZWI7KHK8F | KEGG_Ref = {{keggcite|changed|kegg}} | KEGG = D09913 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 1170047 | C=7 | H=5 | I=1 | N=2 | O=3 | molecular_weight = 292.03 g/mol | smiles = c1cc(c(cc1C(=O)N)[N+](=O)[O-])I | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C7H5IN2O3/c8-5-2-1-4(7(9)11)3-6(5)10(12)13/h1-3H,(H2,9,11) | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = MDOJTZQKHMAPBK-UHFFFAOYSA-N }} Iniparib (INN,[1] previously known as BSI 201) was a drug candidate for cancer treatment. It was originally believed to act as an irreversible inhibitor of PARP1 (hence, a PARP inhibitor) and possibly other enzymes through covalent modification,[2][3] but its effects against PARP were later disproven.[4][5] It underwent clinical trials for treatment of some types of breast cancer,[6][7] but was discontinued after disappointing phase III clinical trials. HistoryIniparib was the first putative PARP inhibitor to commence phase III clinical trials.[8] The first was for breast cancer,[9] another was for squamous-cell lung cancer.[10] Preliminary results in June 2009 on triple-negative breast cancer were promising.[11] Later results showed increased median survival of triple-negative breast cancer patients from 7.7 to 12.2 months.[12][13][14] In 2009, the FDA began fast-tracking the new drug application of iniparib for triple-negative breast cancer. However, phase III results disclosed in January 2011 were disappointing.[15][16] Iniparib was also studied as a potential chemotherapeutic agent in the fight against malignant glioma, including glioblastoma. Glioma is a resilient type of primary brain tumor (not metastatic) that currently has limited effective therapies, especially for patients whose tumors are in an inoperable location of the brain, such as the interior of the brainstem. During the 2013 American Society of Clinical Oncology conference, Sanofi disclosed that iniparib failed to help lung-cancer patients in a late-stage trial, prompting the company to end research into the once-promising compound and take a $285 million charge.[15][17] References1. ^{{cite web | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65 | url = http://www.who.int/medicines/publications/druginformation/innlists/RL65.pdf | publisher = World Health Organization | accessdate = 20 December 2016 | page = 68 | date = 2011}} 2. ^Development of PARP Inhibitors: An Unfinished Story, Jan 2010 3. ^http://www.biparsciences.com/000011.html {{webarchive |url=https://web.archive.org/web/20100623054505/http://www.biparsciences.com/000011.html |date=June 23, 2010 }} 4. ^{{cite journal | pmid = 22128301 | year = 2012 | last1 = Liu | first1 = X | last2 = Shi | first2 = Y | last3 = Maag | first3 = DX | last4 = Palma | first4 = JP | last5 = Patterson | first5 = MJ | last6 = Ellis | first6 = PA | last7 = Surber | first7 = BW | last8 = Ready | first8 = DB | last9 = Soni | first9 = NB | last10 = Ladror | first10 = U. S. | last11 = Xu | first11 = A. J. | last12 = Iyer | first12 = R. | last13 = Harlan | first13 = J. E. | last14 = Solomon | first14 = L. R. | last15 = Donawho | first15 = C. K. | last16 = Penning | first16 = T. D. | last17 = Johnson | first17 = E. F. | last18 = Shoemaker | first18 = A. R. | title = Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a Bona Fide PARP inhibitor | volume = 18 | issue = 2 | pages = 510–23 | doi = 10.1158/1078-0432.CCR-11-1973 | journal = Clinical Cancer Research| display-authors = 8 }} 5. ^{{cite journal | pmid = 22291137 | year = 2012 | last1 = Patel | first1 = AG | last2 = De Lorenzo | first2 = SB | last3 = Flatten | first3 = KS | last4 = Poirier | first4 = GG | last5 = Kaufmann | first5 = SH | title = Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase in Vitro | volume = 18 | issue = 6 | pages = 1655–62 | doi = 10.1158/1078-0432.CCR-11-2890 | pmc = 3306513 | journal = Clinical Cancer Research}} 6. ^BSI 201 7. ^{{cite news |url=https://www.reuters.com/article/healthNews/idUSTRE54U1FV20090531 |title=New breast cancer drugs block cell repair enzyme | work=Reuters | date=2009-05-31}} 8. ^{{cite web |url=http://www.p-d-r.com/ranking/Wolters%20Kluwer%20Health/July09/PARPi.WKHealth.29Jul09.pdf |title=PARP Inhibitors in Oncology. Chemosensitizers or Single-Agent Therapeutics? |date=July 2009 }}{{dead link|date=November 2017 |bot=InternetArchiveBot |fix-attempted=yes }} 9. ^{{cite web |url=http://clinicaltrials.gov/ct2/show/NCT00938652 |title=A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer }} 2009 to 2012, Primary completion date June 2011 10. ^{{cite web |url=http://clinicaltrials.gov/ct2/show/NCT01082549 |title=Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer (ECLIPSE) }} 2010 to 2014, PCD 2012 11. ^{{cite news |url=http://www.dancewithshadows.com/pillscribe/sanofi%E2%80%99s-new-drug-bsi-201-offers-to-treat-the-toughest-breast-cancer/ |title=Sanofi’s new drug BSI 201 offers to treat the toughest breast cancer |date=3 June 2009 |access-date=2009-11-17 |archive-url=https://web.archive.org/web/20091018233201/http://www.dancewithshadows.com/pillscribe/sanofi%E2%80%99s-new-drug-bsi-201-offers-to-treat-the-toughest-breast-cancer/# |archive-date=2009-10-18 |dead-url=yes |df= }} 12. ^{{cite web |url=http://www.medpagetoday.com/MeetingCoverage/SABCS/17496 |title=SABCS: PARP Inhibitor Data Called 'Spectacular' |date=Dec 2009 }} 13. ^{{cite news |url=http://www.internalmedicinenews.com/news/oncology-hematology/single-article/parp-inhibitor-adds-nearly-5-months-to-breast-cancer-survival/5b8b2da248.html |title=PARP Inhibitor Adds Nearly 5 Months to Breast Cancer Survival |date=11 Oct 2010 }} 14. ^{{cite journal |title=Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer |author=O'Shaughnessy |year=2011 |doi=10.1056/NEJMoa1011418 |last2=Osborne |first2=Cynthia |last3=Pippen |first3=John E. |last4=Yoffe |first4=Mark |last5=Patt |first5=Debra |last6=Rocha |first6=Christine |last7=Koo |first7=Ingrid Chou |last8=Sherman |first8=Barry M. |last9=Bradley |first9=Charles |journal=New England Journal of Medicine |volume=364 |issue=3 |pages=205–214 |pmid=21208101 |display-authors=etal}} 15. ^1 {{cite web |url=http://www.fiercebiotech.com/story/sanofi-breast-cancer-drug-flunks-phase-iii-trial/2011-01-27 |title=Sanofi breast cancer drug flunks Phase III trial}} 16. ^{{cite journal |url=http://jco.ascopubs.org/content/32/34/3840.abstract |authors=Joyce O'Shaughnessy, Lee Schwartzberg, Michael A. Danso |title=Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer |journal=J. Clin. Oncol. |volume=32 |issue=34 |pages=3840–7 |doi=10.1200/JCO.2014.55.2984 |pmid=25349301 |date=2014-12-01 |accessdate=2015-07-24|display-authors=etal}} 17. ^{{cite web | url = https://www.bloomberg.com/news/2013-06-03/sanofi-ends-iniparib-research-plans-285-million-charge.html | title = Sanofi Ends Iniparib Research}} 4 : Abandoned drugs|Benzamides|Nitrobenzenes|Iodoarenes |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。